1 minute read

Mangesh Kulkarni, PhD

BSPII, Suite 300 | 450 Technology Drive | Pittsburgh, PA 15219 P: 443-616-5495

kulkarnim2@upmc.edu Research Assistant Professor

Modulation of Molecular Disarray using Biomaterials-based Therapy

Dr. Mangesh Kulkarni is a research assistant professor of Bioengineering at University of Pittsburgh and a faculty member of McGowan institute of regenerative medicine. Following the completion of MD and M.Tech degrees in India, he received his PhD in biomedical engineering from National University of Ireland Galway in 2012. Dr. Kulkarni’s research is primarily translational in the fields of tissue engineering, regenerative medicine and molecular therapeutics. Most of the regenerative processes are complex with multiscale structural/ functional organization and spatio-temporally controlled attributes. Therefore, a holistic understanding of stem cell biology & molecular events and development & application of novel bioengineering solutions is central to regenerative medicine. Employing techniques such as next generation sequencing, digital PCR, in situ hybridization, Dr. Kulkarni investigates the molecular signature of disease state to pinpoint players in the etiopathology of the disease aspects, for example regeneration and repair in diabetes. Dr. Kulkarni focuses on development of biomaterials based regenerative therapies that can be tuned either a) for modulating the function of stem cells and/or immune cells by delivery of the deficient biomolecules or repression of the overexpressed biomolecules or b) utilizing stem cells as factories producing an array of immunomodulatory and regenerative factors. He is working in close collaboration with Dr. Bryan Brown in the areas of innate immunity and host response to biomaterials.

Research Interests

• Tissue Engineering • Regenerative Medicine • Development of Biomaterials-based Delivery Systems • Molecular Diagnostics and Therapeutics, particularly involving

Non-coding RNA • Cell-free Therapeutic Strategies such as Stem Cells Secretome Therapy • Innate Immunity and Host Response to Biomaterials

This article is from: